Join us for an insightful webinar exploring Lonza’s comprehensive portfolio of primary human cells and optimized media systems.
Discover how these foundational tools empower researchers to develop advanced, complex in vitro models that deliver improved biological relevancy and predictive power. Lonza scientists will guide attendees through applications in angiogenesis research, from simple qualitative screening approaches to sophisticated co-culture models enabling precise quantitative analysis.
In the second half of the session, our collaborator Aracari Biosciences will present their cutting-edge vascularized organ and tumor chips. These innovative platforms offer physiologically relevant environments that accelerate drug development by providing more accurate and meaningful results.
Whether you’re advancing disease modeling or optimizing drug screening, this webinar will provide valuable insights into building more predictive and translational in vitro systems.
Key Topics Include:
- Receive an introduction to how primary cells can be utilized for optimized screening and testing.
- Learn how biologically-relevant and predictive models can be built using the co-culture of primary cells.
- Gain insight regarding the importance of vascularization in 3D models and how to achieve it.
Presenters
Senior Technical Support Specialist, R&D
Lonza
Scott joined Lonza in January 2023 as a project manager and marketing content developer for the Biosciences Cell Discovery team. He obtained his Masters of Science from Ohio State University (USA) in 2016, and later found his calling in scientific project management. He has co-authored two technical notes on angiogenesis using human umbilical vein endothelial cells that can be found on the Lonza website.
CSO and Co-Founder
Aracari Biosciences, Inc.
Dr. Hughes is also Chancellor’s Professor of Molecular Biology & Biochemistry, and Biomedical Engineering at UC Irvine. Dr. Hughes’ research focuses on the development and growth of blood vessels and spans multiple scales – from understanding the basic molecular mechanisms of angiogenesis, to engineering of artificial tissues. Recently his lab has been pioneering “Body-on-Chip” technology, which allows for micro-organs to be grown on a “chip”, each with its own blood vessel network. Tissues generated include liver, pancreas, lung, various tumors and brain, including a blood-brain barrier. These devices are gaining use as screening tools for new therapeutic drugs, and the technology, co-developed by two co-founders Dr. Steve George and Dr. Abe Lee, is now licensed to Aracari Biosciences. Dr. Hughes has published over 130 peer-reviewed manuscripts, and in 2014 was elected a Fellow of the American Association for the Advancement of Science (AAAS).
Production Partner
Lonza Bioscience
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our colleagues work alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.
Additional Content From Lonza Bioscience
Building New Approach Methodologies (NAMs) and Complex In Vitro Assays
Learn how Lonza’s primary human cells, media, and reagents support advanced in vitro models for drug discovery, toxicity testing, and reducing animal use.
Advances in Preclinical Research using Human Co-culture Models: Applications in Immunology, Infectious Disease, and Oncology
Join Dr. Ethan Shelkey as he discusses human primary co-culture models with immune cells that are used in infectious disease studies and cancer therapeutic testing.
Cell-Based Assays for Immuno-oncology
Join Lonza scientist Ethan Shelkey as he explores how cell-based assays can assess immune activation and support immunotherapy development.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability
Join our webinar to discover how to de-risk ADC development through the integration of AI-driven analytics, mouse clinical trials and specialized translational models.
From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Learn how patient-derived organoids predict treatment response in metastatic colorectal cancer and explore findings from the OPTIC study on drug sensitivity and clinical outcomes.
De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms
In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D - from target identification and confirmation to receptor/drug validation and translational decision-making.